tradingkey.logo

Compass Pathways Announces Dosing Complete For All Participants In Part A Of Phase 3 Comp005 Trial Of Comp360 Psilocybin

ReutersApr 22, 2025 10:03 AM

- Compass Pathways PLC CMPS.O:

  • COMPASS PATHWAYS ANNOUNCES DOSING COMPLETE FOR ALL PARTICIPANTS IN PART A OF PHASE 3 COMP005 TRIAL OF COMP360 PSILOCYBIN FOR TREATMENT-RESISTANT DEPRESSION

  • COMPASS PATHWAYS PLC - TOP-LINE 6-WEEK PRIMARY ENDPOINT RESULTS EXPECTED IN LATE JUNE

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI